Search | Clinical Trials Finder

Conditions: Advanced or Metastatic NSCLC
Interventions: Datopotamab deruxtecan, KEYTRUDA®, Carboplatin, Cisplatin; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years and older
Enrollment: 145 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 9
States / cities: Scottsdale, Arizona • Duarte, California • Washington D.C., District of Columbia + 5 more

Conditions: Breast Cancer
Interventions: trastuzumab, paclitaxel; Biological · Drug
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: Not listed
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2001
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Malignant Melanoma
Interventions: Cobimetinib, vemurafenib; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 131 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2017
U.S. locations: 9
States / cities: Los Angeles, California • San Francisco, California • Santa Monica, California + 6 more

Conditions: Breast Cancer
Interventions: Trastuzumab Deruxtecan; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 506 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 2
States / cities: Boston, Massachusetts • Durham, North Carolina

Conditions: Childhood Acute Lymphoblastic Leukemia in Remission, Childhood Acute Myeloid Leukemia in Remission, Childhood Chronic Myelogenous Leukemia, Childhood Myelodysplastic Syndromes, Chronic Phase Chronic Myelogenous Leukemia, de Novo Myelodysplastic Syndromes, Juvenile Myelomonocytic Leukemia, Previously Treated Myelodysplastic Syndromes, Recurrent Childhood Acute Lymphoblastic Leukemia, Secondary Myelodysplastic Syndromes
Interventions: allogeneic bone marrow transplantation, laboratory biomarker analysis, filgrastim; Procedure · Other · Biological
Lead sponsor: Children's Oncology Group; Network
Eligibility: Up to 21 Years
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2022
U.S. locations: 21
States / cities: Arcadia, California • San Francisco, California • Aurora, Colorado + 17 more

Conditions: Metastatic Liver Cancer, Secondary Liver Cancer, Liver Neoplasm
Interventions: Radiofrequency Ablation (RFA), Chemotherapy; Device · Drug
Lead sponsor: Boston Scientific Corporation; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 2
States / cities: New York, New York • Cleveland, Ohio

Conditions: Metastatic Squamous Cell Carcinoma of the Hypopharynx, Metastatic Squamous Cell Carcinoma of the Larynx, Metastatic Squamous Cell Carcinoma of the Oral Cavity, Metastatic Squamous Cell Carcinoma of the Oropharynx, Recurrent Hypopharyngeal Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma, Recurrent Oral Cavity Squamous Cell Carcinoma, Recurrent Oropharyngeal Squamous Cell Carcinoma, Stage IV Hypopharyngeal Squamous Cell Carcinoma AJCC v7, Stage IV Laryngeal Squamous Cell Carcinoma AJCC v7, Stage IV Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7, Stage IV Oropharyngeal Squamous Cell Carcinoma AJCC v7, Stage IVA Hypopharyngeal Squamous Cell Carcinoma AJCC v7, Stage IVA Laryngeal Squamous Cell Carcinoma AJCC v7, Stage IVA Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7, Stage IVA Oropharyngeal Squamous Cell Carcinoma AJCC v7, Stage IVB Hypopharyngeal Squamous Cell Carcinoma AJCC v7, Stage IVB Laryngeal Squamous Cell Carcinoma AJCC v7, Stage IVB Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7, Stage IVB Oropharyngeal Squamous Cell Carcinoma AJCC v7, Stage IVC Hypopharyngeal Squamous Cell Carcinoma AJCC v7, Stage IVC Laryngeal Squamous Cell Carcinoma AJCC v7, Stage IVC Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7, Stage IVC Oropharyngeal Squamous Cell Carcinoma AJCC v7
Interventions: Carboplatin, Cisplatin, Docetaxel, Erlotinib Hydrochloride, Laboratory Biomarker Analysis, Pharmacological Study, Placebo, Quality-of-Life Assessment; Drug · Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 123 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2020
U.S. locations: 5
States / cities: Houston, Texas • Nassau Bay, Texas • Sugar Land, Texas + 1 more

Conditions: Metastatic Colorectal Cancer
Interventions: Selinexor, Pembrolizumab, Trifluridine, Tipiracil; Drug
Lead sponsor: Karyopharm Therapeutics Inc; Industry
Eligibility: 18 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 3
States / cities: Los Angeles, California • Newark, Delaware • Plantation, Florida

Conditions: Breast Neoplasms, Metastases, Neoplasm
Interventions: ZD6474; Drug
Lead sponsor: Genzyme, a Sanofi Company; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2003
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Breast Cancer; HER2-positive; Metastatic
Interventions: Trastuzumab deruxtecan, Placebo, Taxane, Pertuzumab, Trastuzumab; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 1,157 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2029
U.S. locations: 30
States / cities: Tucson, Arizona • Springdale, Arkansas • Glendale, California + 25 more

Conditions: Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Carcinoma
Interventions: Cetuximab, Laboratory Biomarker Analysis, Tivantinib; Biological · Other · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 81 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 24
States / cities: Scottsdale, Arizona • Duarte, California • Los Angeles, California + 19 more

Conditions: Melanoma (Skin)
Interventions: recombinant interferon alfa, radiation therapy; Biological · Radiation
Lead sponsor: Eastern Cooperative Oncology Group; Network
Eligibility: 18 Years to 120 Years · Female only
Enrollment: 167 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1999
U.S. locations: 23
States / cities: Atlanta, Georgia • Decatur, Georgia • Chicago, Illinois + 15 more

Conditions: Breast Cancer
Interventions: gemcitabine/carboplatin, Iniparib; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 519 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 102
States / cities: Birmingham, Alabama • Sedona, Arizona • Jonesboro, Arkansas + 98 more

Conditions: Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma in the Soft Tissue, Prostate Carcinoma Metastatic in the Bone, Stage IV Prostate Adenocarcinoma AJCC v7
Interventions: Abiraterone Acetate, Androgen deprivation therapy, Cabazitaxel, Prednisone; Drug
Lead sponsor: ECOG-ACRIN Cancer Research Group; Network
Eligibility: 18 Years and older · Male only
Enrollment: 223 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2028
U.S. locations: 665
States / cities: Fairbanks, Alaska • Goodyear, Arizona • Kingman, Arizona + 437 more

Conditions: Metastatic Cancer, Prostate Cancer
Interventions: Docetaxel, Imatinib Mesylate; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: Male only
Enrollment: 116 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2008
U.S. locations: 3
States / cities: Boston, Massachusetts • New York, New York • Houston, Texas

Conditions: Metastatic BRCA Hereditary Breast Carcinoma, Metastatic Breast Carcinoma, Metastatic Malignant Neoplasm in the Brain, Metastatic Triple-Negative Breast Carcinoma, Recurrent Breast Carcinoma, Stage IV Breast Cancer AJCC v6 and v7
Interventions: Cisplatin, Laboratory Biomarker Analysis, Placebo Administration, Veliparib; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 344 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2025
U.S. locations: 798
States / cities: Anchorage, Alaska • Fort Smith, Arkansas • Hot Springs, Arkansas + 542 more

Conditions: Leukemia
Interventions: lintuzumab, cytarabine, etoposide, mitoxantrone hydrochloride; Biological · Drug
Lead sponsor: Facet Biotech; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2000
U.S. locations: 40
States / cities: Los Angeles, California • Orange, California • Sacramento, California + 29 more

Conditions: Chronic Myeloproliferative Disorders, Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
Interventions: decitabine, romidepsin; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2005
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Non-small Cell Lung Cancer
Interventions: pembrolizumab, pemetrexed, carboplatin, cisplatin, saline solution; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 492 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 19
States / cities: Los Angeles, California • Monterey, California • Orange, California + 14 more

Conditions: ER-Positive HER2-Negative Breast Cancer
Interventions: AZD9833, AZD9833 Placebo, Anastrozole, Anastrozole placebo, Letrozole, Letrozole placebo, Palbociclib, Abemaciclib, Luteinizing hormone-releasing hormone (LHRH) agonist, Ribociclib; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 315 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 64
States / cities: Phoenix, Arizona • Hot Springs, Arkansas • Little Rock, Arkansas + 56 more

Conditions: Adenoid Cystic Carcinoma
Interventions: Radiation, Pembrolizumab; Radiation · Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Non-Small Cell Lung Cancer
Interventions: bevacizumab, placebo, erlotinib HCl; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 1,145 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2014
U.S. locations: 177
States / cities: Mobile, Alabama • Fort Smith, Arizona • Scottsdale, Arizona + 160 more

Conditions: Leukemia, Myelodysplastic Syndrome
Interventions: bortezomib, vorinostat; Drug
Lead sponsor: Masonic Cancer Center, University of Minnesota; Other
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Leukemia
Interventions: PR1 leukemia peptide vaccine, sargramostim, placebo; Biological · Other
Lead sponsor: The Vaccine Company; Industry
Eligibility: 18 Years and older
Enrollment: 244 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2005
U.S. locations: 15
States / cities: Scottsdale, Arizona • Los Angeles, California • South San Francisco, California + 10 more

Search by objective public record fields.

Datopotamab Deruxtecan (Dato-DXd) in Combination With Pembrolizumab With or Without Platinum Chemotherapy in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer (TROPION-Lung02)

Paclitaxel With or Without Trastuzumab Following Peripheral Stem Cell Transplantation in Treating Patients With Refractory Stage IV Breast Cancer

A Study of Vemurafenib and GDC-0973 (Cobimetinib) in Participants With BRAFV600E Mutation-Positive Metastatic Melanoma

A Study of T-DXd in Participants With or Without Brain Metastasis Who Have Previously Treated Advanced or Metastatic HER2 Positive Breast Cancer

Donor Bone Marrow Transplant With or Without G-CSF in Treating Young Patients With Hematologic Cancer or Other Diseases

Study Comparing Radio Frequency Ablation Plus Chemotherapy and Chemotherapy Alone in Patients With Secondary Liver Metastases

Combination Chemotherapy With or Without Erlotinib Hydrochloride in Treating Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck

A Study to Evaluate the Safety and Efficacy of Selinexor With or Without Pembrolizumab Versus Standard of Care in Previously Treated Metastatic Colorectal Cancer With RAS Mutations

This Study is to Assess the Efficacy and Safety of ZD6474 in Subjects With Metastatic Breast Cancer

Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09)

Cetuximab With or Without Tivantinib in Treating Patients With Head and Neck Cancer That Is Recurrent, Metastatic, or Cannot Be Removed by Surgery

Interferon Alfa-2b With or Without Radiation Therapy in Treating Patients With Melanoma That Has Metastasized to Lymph Nodes in the Neck, Under the Arm, or in the Groin

A Phase 3, Multi-Center Study of Gemcitabine/Carboplatin, With or Without BSI-201, in Patients With ER-, PR-, and Her2-Negative Metastatic Breast Cancer

Abiraterone Acetate and Antiandrogen Therapy With or Without Cabazitaxel and Prednisone in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer Previously Treated With Docetaxel

Docetaxel With or Without Imatinib Mesylate in Treating Patients With Androgen-Independent Prostate Cancer and Bone Metastases

Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases

Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Patients With Refractory or Relapsed Acute Myelogenous Leukemia

Decitabine and FR901228 in Treating Patients With Relapsed or Refractory Leukemia, Myelodysplastic Syndromes, or Myeloproliferative Disorders

Study of Pemetrexed + Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Adults With Tyrosine Kinase Inhibitor- (TKI)-Resistant Epidermal Growth Factor Receptor- (EGFR)-Mutated Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-789/KEYNOTE-789)

Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6)

Pembrolizumab With or Without Radiation in Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma

A Study Comparing Bevacizumab Therapy With or Without Erlotinib for First-Line Treatment of Non-Small Cell Lung Cancer (ATLAS)

Bortezomib and Vorinostat in Treating Patients With High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia

Vaccine Therapy and GM-CSF in Treating Patients With Acute Myeloid Leukemia in Remission